Showing results (331-340 of 395) with videos related to
Sort By:
Pageof 40
Blood|September 26, 2018
Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphomaLorenz Thurner, Klaus-Dieter Preuss, Moritz Bewarder, et al.Haematologica|July 18, 2020
Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphomaLorenz Thurner, Sylvia Hartmann, Moritz Bewarder, et al.The Lancet. Oncology|September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialOthman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma NetworkEva Hoster, Andreas Rosenwald, Françoise Berger, et al.Genes, Chromosomes & Cancer|November 3, 2019
Reconstruction of rearranged T-cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of T-cell prolymphocytic leukemiaPaurnima Patil, Agata Cieslak, Stephan H Bernhart, et al.The Journal of Allergy and Clinical Immunology|February 21, 2017
Human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome activity is regulated by and potentially targetable through Bruton tyrosine kinaseXiao Liu, Tica Pichulik, Olaf-Oliver Wolz, et al.Journal of Cancer Research and Clinical Oncology|October 14, 2022
Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemicVolker Arndt, Daniela Doege, Stefan Fröhling, et al.Cancer Research|April 20, 2019
MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt LymphomaJennifer Hüllein, Mikołaj Słabicki, Maciej Rosolowski, et al.Hemasphere|February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.Pageof 40